Serum p-Glycoprotein and Monomeric C-Reactive Protein are Elevated in Takayasu Arteritis
Darpan Thakare,Kritika Singh,Tooba Qamar,Deeksha Singh,Sandeep Balakrishnan,Upendra Rathore,Neeraj Jain,Manish Ora,Durga Misra
DOI: https://doi.org/10.2147/jir.s490958
IF: 4.5
2024-11-13
Journal of Inflammation Research
Abstract:Darpan Radheshyam Thakare, 1, 2, &ast Kritika Singh, 1, &ast Tooba Qamar, 1 Deeksha Singh, 1 Sandeep Balakrishnan, 1 Upendra Rathore, 1 Neeraj Jain, 3 Manish Ora, 4 Durga Prasanna Misra 1 1 Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, Uttar Pradesh, India; 2 Department of Clinical Immunology and Rheumatology, King George Medical University (KGMU), Lucknow, Uttar Pradesh, India; 3 Department of Radiodiagnosis, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, Uttar Pradesh, India; 4 Department of Nuclear Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, Uttar Pradesh, India &astThese authors contributed equally to this work Correspondence: Durga Prasanna Misra, Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, 226014, Uttar Pradesh, India, Email ; Purpose: Existing biomarkers including C-reactive protein (CRP) do not adequately distinguish active and inactive TAK. We compared serum p-glycoprotein (p-gp)/Multidrug Resistance Protein 1 (MDR1), monomeric CRP (mCRP), CRP, and mCRP:CRP ratio in Takayasu arteritis (TAK) and healthy controls and their relationship with disease activity. Patients and Methods: Serum p-gp mCRP (ELISA) and CRP (nephelometry) were compared between consecutive adults with TAK (> 18 years) enrolled from a prospective cohort (n = 92) and healthy controls (n = 29), and between active vs inactive TAK (n = 46 each). In a subset of active immunosuppressive-naïve TAK (n = 29), correlation was assessed between serum p-gp and p-gp expression on circulating T helper lymphocyte populations: overall (CD4+), Th17 (CD4+IL-17+), Th17.1 (CD4+IL-17+IFN-γ+) lymphocytes [normalized to Tregs (CD4+CD25+FoxP3+)]. Changes in serum p-gp, mCRP, CRP, and mCRP:CRP were compared before and after immunosuppression (n = 29). Data was represented using median (Q1-Q3). Receiver operating characteristics (ROC) curves were generated for TAK vs controls, and active vs inactive TAK with serum p-gp, mCRP, CRP, and mCRP:CRP. Multivariable-adjusted linear regression was used to predict active disease with serum p-gp, mCRP, CRP, or mCRP:CRP. Results: Serum p-gp (11.19 vs 8.05 ng/mL), mCRP (1.61 vs 1.25 μg/L), and CRP (5.40 vs 2.1 mg/L) were elevated in TAK vs controls (p < 0.05 for all). CRP was higher and mCRP:CRP ratio was lower in active vs inactive TAK (p < 0.001). ROC curves identified moderate prediction for active disease with CRP and inactive disease with serum p-gp (area under ROC curve 0.705 and 0.392, respectively). Multivariable-adjusted linear regression confirmed association of CRP with active disease (p = 0.009) and serum p-gp with inactive disease (p = 0.041). In treatment-naïve TAK, serum p-gp negatively correlated with p-gp+Th17.1 lymphocytes (Spearman's rho=− 0.39, p = 0.046). CRP and serum p-gp were significantly lowered following immunosuppressive therapy in treatment-naïve TAK (p < 0.05). Conclusion: Serum p-gp and mCRP are elevated in TAK. Serum p-gp is associated with inactive disease. Keywords: Takayasu arteritis, MDR1 protein, C-reactive protein, large vessel vasculitis, aortoarteritis, disease activity Takayasu arteritis (TAK) is a rare large vessel vasculitis (LVV) commoner in Asian countries than elsewhere. 1–3 TAK is associated with a greater risk of mortality despite predominantly affecting young female adults. 4 The pathology of TAK involves arteritis of the aorta and its major branches, resulting in fibrosis and arterial stenosis. 5 The arterial wall injury in patients with TAK involves the activation of both innate and adaptive immune cells. 5 T lymphocytes in particular have been implicated in the pathogenesis of TAK. Increased circulating Th1 lymphocytes (which secrete interferon-gamma – IFN-γ) and Th17 lymphocytes (which secrete interleukin 17 – IL17) have been observed in patients with TAK as well as in the counterpart LVV of Giant Cell Arteritis (GCA). 6–8 However, unlike GCA, the Th17 lymphocytes from TAK are not responsive to corticosteroids. 6,8 Recently, Th17.1 lymphocytes, a subset of Th17 lymphocytes that secrete both IFN- γ and IL-17 (sharing the phenotypic characteristics of both Th1 and Th17 lymphocytes), have been found to be increased in patients with TAK than in healthy controls and are associated with active disease. 9 The Th17.1 lymphocyte population also expresses the drug efflux protein p-glycoprotein (p-g -Abstract Truncated-
immunology